Login to Your Account

NewCo News

Ablitech Seeking Success by Halting Undesirable Cell Growth

By Marie Powers
Staff Writer

Thursday, January 26, 2012
Launched in 2006 after its co-founder pitched the concept at a Federal Express business plan competition, Ablitech Inc., started the New Year in a new location. The small biotech relocated from Hattiesburg, Miss., to the BioPark at the University of Maryland, where it is working to develop treatments for heterotropic ossification (HO) – a painful bone growth that occurs after severe trauma such as a concussion blast or amputation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription